EphMRA 2016 roundup
21 - 23 June 2016, Frankfurt, Germany
We were delighted to sponsor, attend and present at this year’s EphMRA Annual Conference in Frankfurt, Germany on 21 - 23 June. Representing Research Partnership were Senior Director Angela Duffy and Director and EphMRA board member Richard Head. Also in attendance was Associate Director An-Hwa Lee who, as a member of the EphMRA Learning and Development Committee, convened one of three of the pre-conference training workshops entitled ‘Medical Device Research: Leveraging current market research trends to optimise medical device lifecycle management.”
The conference was well attended and opened with an inspiring presentation from author Jim Lawless, one of the world’s leading keynote speakers. During his thought-provoking presentation ‘Taming Tigers: Accomplishing Mission Impossible’ Jim talked about how accomplishing ‘mission impossible’ depends upon our ability to adapt and create disruptive changes, to seize opportunities, and above all empower others and inspire action.
Examples of Therapy Watch data used at conferences
View past examples of Therapy Watch data being used at conferences
What next for biosimilars?
Biosimilar medicines appear to present a significant opportunity to introduce cutting-edge therapies to the treatment landscape for many diseases, while also addressing the cost-effectiveness demands now being made on global healthcare systems. However, these drugs aren’t cheap or easy to manufacture and come with considerable marketing challenges.
Join market research consultants Laurent Chanroux and Richard Head for this complimentary webinar in which they will explore and compare biosimilars in RA and diabetes.
Understanding the Patient Journey guide
The patient journey is changing. Patients are now much more educated and engaged. They have access to information and want to be involved in decisions around their treatment programme. Technology is changing the way that healthcare is delivered and the way that patients experience healthcare. The journey is also more complex, with increasing number of healthcare professionals having to work together to provide care.
As pharma companies increasingly recognise the challenges of expecting physicians to carry the weight of their brand strategy, greater emphasis is being placed upon delivering services which ease the burden upon the physician and address the needs of other stakeholders involved in treating the patient.
Understanding the Chronic Disease Patient Journey in Emerging Markets
With growing urban populations and increasing purchasing power, emerging markets remain an attractive prospect for growth. A high proportion of the urban emerging market population already suffer from chronic diseases and prevalence is set to further increase as lifestyles become closer to those in the West.
The chronic disease patient is a critical stakeholder in emerging markets because they often have to pay for their healthcare out of pocket. Moreover these markets often don’t have formal primary care systems, so the patient is the only constant in the journey. Understanding their journey is critical in order to fully exploit these potential new markets.